Aratana Therapeutics, Inc. (NASDAQ:PETX) Expected to Post Quarterly Sales of $4.60 Million

Equities analysts forecast that Aratana Therapeutics, Inc. (NASDAQ:PETX) will report $4.60 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aratana Therapeutics’ earnings. The highest sales estimate is $4.70 million and the lowest is $4.50 million. Aratana Therapeutics reported sales of $38.05 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 87.9%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, August 3rd.

On average, analysts expect that Aratana Therapeutics will report full year sales of $4.60 million for the current year, with estimates ranging from $19.30 million to $28.80 million. For the next year, analysts forecast that the firm will report sales of $58.81 million per share, with estimates ranging from $38.50 million to $82.42 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). Aratana Therapeutics had a negative net margin of 66.72% and a negative return on equity of 14.95%. The business had revenue of $3.80 million during the quarter, compared to the consensus estimate of $3.05 million. During the same period last year, the business posted ($0.52) EPS. Aratana Therapeutics’s revenue was up 2135.3% on a year-over-year basis.

A number of equities research analysts have issued reports on PETX shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, May 5th. ValuEngine downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 31st. Stifel Nicolaus reduced their price objective on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.00.

Shares of Aratana Therapeutics (NASDAQ:PETX) opened at 6.87 on Friday. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73. The company has a 50-day moving average of $7.04 and a 200 day moving average of $6.50. The firm’s market capitalization is $260.76 million.

TRADEMARK VIOLATION WARNING: “Aratana Therapeutics, Inc. (NASDAQ:PETX) Expected to Post Quarterly Sales of $4.60 Million” was originally published by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/aratana-therapeutics-inc-nasdaqpetx-expected-to-post-quarterly-sales-of-4-60-million-updated/1308002.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC increased its position in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Aratana Therapeutics by 8.6% in the first quarter. Goldman Sachs Group Inc. now owns 65,415 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 5,165 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its position in Aratana Therapeutics by 7.6% in the first quarter. Grandeur Peak Global Advisors LLC now owns 383,363 shares of the biopharmaceutical company’s stock worth $2,032,000 after buying an additional 27,225 shares in the last quarter. Tudor Investment Corp ET AL increased its position in Aratana Therapeutics by 335.4% in the first quarter. Tudor Investment Corp ET AL now owns 56,600 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 43,600 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares in the last quarter. 68.08% of the stock is owned by hedge funds and other institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.